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Chemical Synthesis and Characterization 
 
Scheme 1. a) i. AcOH, 4-CyPhCHO, ii. NaCNBH3, MeOH, 6h, 45 °C (83 %); b) FMOC-Gly-OH, PPh3Cl2, 
CHCl3, 0.5, 110 °C (76 %); c) piperidine, DMF, 0.5 h, RT (62 %); d) F5BnBr, Cs2CO3, DMF, RT (87 %); e) 




Scheme 2. Synthesis of N-methyl Analogs: a) R1SO2Cl, DIPEA, DCM, 16 h, RT (73-89 %); b) 
LiOH.H2O, THF:H2O, 3:1, 0.5 h, RT (96-100 %); c) 4, PPh3Cl2, CHCl3, 0.5, 110 °C (42-43 %); f) H2, 10 % 




Scheme 3. Synthesis of Top N-Alkyl Compounds: a) R1SO2Cl, K2CO3, MeCN, 16 h, 0 °C RT (48-83 %); 





General Procedure A: Secondary Sulfonamide Coupling  
Secondary amine 5.1 (1.0 equiv.) was dissolved in anhydrous dichloromethane (DCM) with 
diisopropylethylamine (DIPEA) (1.3 equiv.). Sulfonyl chloride (1.2 equiv.) was added and the reaction 
mixture was stirred at RT for 16 hours. Upon completion, solvent was removed under reduced pressure and 
the crude product was then purified using flash column chromatography using a mixture of hexanes and 
ethyl acetate (EtOAc) as the eluent. 
General Procedure B: Global deprotection of Benzylated Salicyclic Acid  
The dibenzyl protected salicyclic acid (1 equiv.) was dissolved in a stirred solution of MeOH/THF (1:1) (0.1 
M). The solution was degassed thoroughly before careful addition of 10% Pd/C (10 mg/mmol). H2 gas was 
bubbled through the solvent for 5 mins before the solution was put under an atmosphere of H2 gas and 
stirred continuously for 6 hours. The H2 gas was evacuated and the reaction filtered (to remove the Pd 
catalyst) and concentrated under reduced pressure. Crude product was then purified using flash column 
chromatography using a mixture of DCM, MeOH and acetic acid (AcOH) as the eluent (generally 92 % 
DCM, 7 % MeOH and 1 % AcOH in a 1:2 ratio with DCM was utilized). 
General Procedure C: Primary Sulfonamide Coupling  
From primary amine 6 (1.0 equiv.) which was dissolved in anhydrous acetonitrile (MeCN) with K2CO3 (1.1 
equiv.) and 4 Å molecular sieves and cooled to 0 °C. Sulfonyl chloride (1.0 equiv.) was added and the 
reaction mixture was allowed to warm to room temperature. After 6 hours the solution was filtered through 
cotton to remove molecular sieves and excess solvent was removed under reduced pressure. The 
concentrated mixture was diluted with DCM, then washed with 1M HCl, saturated NaHCO3, H2O and brine, 
then dried over Na2SO4. Crude product was then purified using flash column chromatography using a 
mixture of hexanes and EtOAc as the eluent. 
General Procedure D: Sulfonamide Alkylation  
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Activated alkyl halides (1.1 equiv.) were added to a stirred suspension of sulfonamide 13a-d (1 equiv.) and 
Cs2CO3 (1.5 equiv.) in DMF. After 3 hours the mixture was diluted with H2O then the product was extracted 
into EtOAc. Organics were combined and washed with 1 M HCl, saturated NaHCO3, H2O and brine, then 
dried over Na2SO4 and concentrated under reduced pressure. Crude products were purified using flash 
column chromatography using a mixture of hexanes and EtOAc as the eluent. 
General Procedure E: PPh3Cl2 Peptide Coupling 
Carboxylic acid (1 equiv.) was stirred at room temperature with PPh3Cl2 in CHCl3 for 15 minutes to form 
the activated acid. Aniline (1 equiv.) was added and the mixture was heated to 110 °C for 30 minutes using 
a Biotage Initiator microwave reactor. Upon completion, CHCl3 was removed under reduced pressure and 
the crude product was purified using flash column chromatography using a mixture of hexanes and EtOAc 
as eluent. 
Compounds 1, 1a-d, 2 and 2a-d were prepared as previously reported. 
 
3, benzyl 4-amino-2-(benzyloxy)benzoate 
Prepared as previously reported; δH (400 MHz, d6-DMSO) 5.07 (s, 2H, CH2), 5.21 (s, 2H, CH2), 5.99 (br s, 
2H, NH2), 6.18 (d of d, J = 8.6 and 1.8 Hz, 1H, CH), 6.32 (d, J =1.7 Hz, 1H, CH), 7.28-7.38 (8H, m, CH), 
7.47 (d, J = 7.2 Hz, 2H, CH), 7.60 (d, J = 8.6 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 65.8, 70.2, 99.1, 106.7, 
109.0, 126.3, 126.8, 127.5, 127.7, 127.9, 128.1, 128.3, 128.4, 134.3, 136.6, 136.7, 152.2, 160.7, 165.7; 





4, benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate 
To a solution of primary aniline (3) (2.65 g, 8.0 mmol) and acetic acid (0.26 g, 4.4 mmol) stirred in 
anhydrous MeOH (0.1 M) with activated 4 Å mol. sieves was added 4-cyclohexylbenzaldehyde (1.5 g, 8.0 
mmol). The solution was then heated to 45 °C for 3 hr then NaCNBH3 (0.75 g, 12.0 mmol) was added and 
the reaction was heated at 45 °C overnight. Crushed molecular sieves were filtered and washed thoroughly 
with CH2Cl2. The filtrate was collected and concentrated in vacuo then washed with saturated sodium 
bicarbonate, water, brine then dried over Na2SO4. Solvents were removed under reduced pressure to give 
compound 4 (3.3 g, 6.6 mmol, 83%); δH (400 MHz, d-CDCl3) 1.25-1.48 (m, 5H, CH2), 1.74 -1.95 (m, 5H, 
CH2), 2.48-2.52 (m, 1H, CH), 4.28 (s, 2H, CH2), 4.49 (br s, 1H, NH), 5.08 (s, 2H, CH2), 5.32 (s, 2H, CH2), 
6.17 (d, J =2.0 Hz, 1H, CH), 6.21 (d of d, J = 8.6 and 2.0 Hz, 1H, CH), 7.19-7.27 (m, 4H, 4 CH), 7.28-7.37 
(m, 6H, 6 CH), 7.40-7.49 (m, 4H, 4 CH), 7.85 (d, J = 8.6 Hz, 1H, 1 CH); δC (100 MHz, d-CDCl3) 26.0, 
26.7, 34.3, 44.1, 47.3, 65.7, 70.3, 97.1, 104.8, 108.2, 126.8, 127.0, 127.4, 127.5, 127.6, 127.9, 128.2, 128.3, 








Fmoc-glycine-OH (1.13g, 3.80 mmol) was stirred at room temperature with PPh3Cl2 (2.76 g, 8.30 mmol) in 
CHCl3 for 15 minutes to form the activated acid. Aniline 4 (1.75g, 3.46 mmol) was added and the solution 
was heated to 110 °C for 30 minutes using a Biotage Initiator microwave reactor. Upon completion, CHCl3 
was removed under reduced pressure and the crude product was purified using flash column 
chromatography using a mixture of hexanes and EtOAc as eluent (5, 2.08 g, 76 %) ; δH (400 MHz, d-
CDCl3) 1.31-1.54 (m, 5H, CH2), 1.70-1.90 (m, 5H, CH2), 2.17 (s, 2H, CH2), 2.40-2.55 (m, 1H, CH), 3.68 (s, 
2H, CH2), 4.23 (t, J = 7.0 Hz, 1H, CH), 4.36 (d, J = 7.0 Hz, 2H, CH2), 4.83 (s, 2H, CH2), 4.92 (s, 2H, CH2), 
5.35 (s, 2H, CH2), 5.71 (s (br), 1H, NH), 6.52 (s, 1H, CH), 6.70 (d, J = 8.0 Hz, 1H, CH), 7.07 (d, J = 8.0 Hz, 
2H, CH), 7.13 (d, J = 8.0 Hz, 2H, CH), 7.27-7.43 (m, 14H, CH), 7.61 (d, J = 7.4 Hz, 2H, CH), 7.77 (d, J = 





6, benzyl 4-(2-amino-N-(4-cyclohexylbenzyl)acetamido)-2-(benzyloxy)benzoate 
Compound 5 was dissolved in a 5 % solution of piperidine in DMF and stirred for 30 minutes at room 
temperature. Upon completion the reaction mixture was diluted with H2O and organics were extracted into 
EtOAc. Combined organics were then washed with saturated NaHCO3, H2O and brine, then dried over 
Na2SO4. Crude product was purified using flash column chromatography in a mixture of 92 % DCM, 7 % 
MeOH, 1 % NH4OH, and DCM in a 1:1 ratio (6, 62 %); δH (400 MHz, d-CDCl3) 1.29-1.43 (m, 5H, CH2), 
1.66-1.88 (m, 5H, CH2), 2.17 (s, 2H, CH2), 2.38-2.51 (m, 1H, CH), 3.06 (s, 2H, CH2), 4.80 (s, 2H, CH2), 
4.90 (s, 2H, CH2), 5.31 (s, 2H, CH2), 6.50 (s, 1H, CH), 6.64 (d, J = 8.0 Hz, 1H, CH), 7.05-7.12 (m, 4H, 
CH), 7.22-7.41 (m, 10H, CH), 7.81 (d, J = 8.0 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 25.7, 26.4, 34.0, 43.8, 
43.9, 52.3, 66.5, 70.2, 113.8, 119.7, 120.0, 126.5, 126.6, 127.6, 127.8, 127.8, 128.1, 128.2, 128.4, 132.6, 








To a stirred solution of primary amine 6 (900 mg, 1.6 mmol) and Cs2CO3 (630 mg, 1.9 mmol), was added 
2,3,4,5,6-pentafluorobenzyl bromide (420 mg, 1.6 mmol). The mixture was stirred at RT for 1 h, then 
diluted with H2O and organics were extracted into EtOAc. Combined organic layers were washed with 
saturated NaHCO3, H2O and brine and dried over Na2SO4. Solvents were removed under reduced pressure 
and the crude product was purified using flash column chromatography with a gradient mixture of hexanes 
and EtOAc to give 7 (1.03g, 87 %); δH (400 MHz, d-CDCl3) 1.15-1.50 (m, 5H, CH2), 1.67-1.96 (m, 5H, 
CH2), 2.18-2.40 (m, 1H, NH), 2.41-2.59 (m, 1H, CH), 3.08 (s, 3H, C3), 3.81 (s, 2H, CH2), 4.79 (s, 2H, CH2), 
4.93 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.47 (s, 1H, CH), 6.67 (d, J = 8.0 Hz, 1H, CH), 7.03 (d, J = 7.8 Hz, 2H, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8a (18.2 mg, 74 %); 
δH (400 MHz, d-CDCl3) 1.29-1.48 (m, 5H, CH2), 1.68-1.92 (m, 5H, CH2), 2.40-2.56 (m, 1H, CH), 83 (s, 2H, 
CH2), 4.63 (s, 2H, CH2), 4.71 (s, 2H, CH2), 4.90 (s, 2H, CH2), 5.33 (s, 2H, CH2), 6.48 (s, 1H, CH), 6.66 (d, J 
= 8.2 Hz, 1H, CH), 6.97 (d, J = 7.6 Hz, 2H, CH), 7.10 (d, J = 8.0 Hz, 2H, CH), 7.27-7.42 (m, 10H, CH) 
7.45-7.52 (m, 2H, CH), 7.54-7.61 (m, 1H, CH), 7.77 (d, J = 7.7 Hz, 2H, CH), 7.82 (d, J = 8.2 Hz, 1H, CH); 
δC (100 MHz, d-CDCl3) 26.2, 27.0, 34.6, 39.9, 44.4, 49.5, 53.0, 67.2, 70.9,113.8, 120.1, 121.5, 127.1, 127.2, 
127.7, 128.2, 128.4, 128.5, 128.7, 128.8, 129.0, 129.1, 129.8, 133.1, 133.4, 133.9, 135.8, 135.8, 139.5, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8b (22.9 mg, 80.6 %); 
δH (400 MHz, d-CDCl3) 1.30-1.46 (m, 5H, CH2), 1.74-2.15 (m, 5H, CH2), 2.32-2.63 (m, 1H, CH), 3.17 (s, 
3H, C3), 3.80 (s, 2H, CH2), 4.63 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.33 (s, 2H, CH2), 6.44 
(s, 1H, CH), 6.63 (d, J = 7.7 Hz, 1H, CH), 6.98 (d, J = 7.6 Hz, 2H, CH), 7.11 (d, J = 7.7 Hz, 2H, CH), 7.23-
7.41 (m, 10H, CH) 7.80 (d, J = 8.1 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.2, 26.9, 34.6, 39.4, 40.7, 44.4, 
49.7, 53.1, 67.2, 70.8,113.8, 120.1, 121.5, 127.2, 127.3, 128.3, 128.4, 128.5, 128.7, 128.8, 129.0, 133.4, 








Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8c (20.7 mg, 64 %); 
δH (400 MHz, d-CDCl3) 1.32-1.43 (m, 5H, CH2), 1.69-1.91 (m, 5H, CH2), 2.43-2.53 (m, 1H, CH), 3.86 (s, 
2H, CH2), 4.62 (s, 2H, CH2), 4.70 (s, 2H, CH2), 4.91 (s, 2H, CH2), 5.34 (s, 2H, CH2), 6.47 (s, 1H, CH), 6.65 
(d, J = 8.0 Hz, 1H, CH), 6.95 (d, J = 8.0 Hz, 2H, CH), 7.12 (d, J = 8.0 Hz, 2H, CH), 7.27-7.41 (m, 10H, 
CH), 7.74 (d, J = 8.2 Hz, 2H, CH), 7.83 (d, J = 8.0 Hz, 1H, CH), 7.92 (d, J = 8.2 Hz, 2H, CH); δC (100 MHz, 
d-CDCl3) 26.2, 27.0, 34.6, 40.0, 44.4, 49.6, 53.1, 67.3, 70.9, 114.0, 120.2, 121.4, 126.1, 126.1, 127.2, 127.2, 
128.3, 128.4, 128.5, 128.5, 128.7, 128.8, 129.1, 129.1, 133.4, 133.8, 135.8, 135.8, 143.0, 148.2, 159.0, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8d (26.9 mg, 83 %); 
δH (400 MHz, d-CDCl3) 1.34-1.44 (m, 5H, CH2), 1.69-1.92 (m, 5H, CH2), 2.39-2.54 (m, 1H, CH), 3.86 (s, 
2H, CH2), 4.62 (s, 2H, CH2), 4.74 (s, 2H, CH2), 4.91 (s, 2H, CH2), 5.34 (s, 2H, CH2), 6.52 (s, 1H, CH), 6.68 
(d, J = 8.1 Hz, 1H, CH), 7.00 (d, J = 8.0 Hz, 1H, CH), 7.11 (d, J = 8.0 Hz, 2H, CH), 7.26-7.41 (m, 10H, 
CH), 7.45 (d, J = 8.5 Hz, 2H, CH), 7.65 (d, J = 7.9 Hz, 2H, CH), 7.83 (d, J = 8.2 Hz, 1H, CH); δC (100 MHz, 
d-CDCl3) 26.2, 27.0, 31.2, 34.6, 35.3, 40.0, 44.4, 49.8, 53.0, 67.2, 70.9, 107.31, 114.1, 120.3, 121.1, 125.9, 
127.1, 127.3, 127.5, 128.2, 128.4, 128.5, 128.7, 128.7, 129.1, 130.4, 133.3, 134.0, 135.8, 148.0, 156.9, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8e (21.4 mg, 68 %); 
δH (400 MHz, d-CDCl3) 1.31-1.47 (m, 5H, CH2), 1.70-1.90 (m, 5H, CH2), 2.39 (s, 3H, CH3), 2.41-2.54 (m, 
1H, CH), 3.84 (s, 2H, CH2), 4.66 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.92 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.52 
(s, 1H, CH), 6.68 (d, J = 8.2 Hz, 1H, CH), 7.00 (d, J = 8.0 Hz, 2H, CH), 7.12 (d, J = 8.0 Hz, 2H, CH), 7.27-
7.42 (m, 12H, CH), 7.55 (d, J = 7.6 Hz, 1H, CH), 7.57 (s, 1H, CH), 7.84 (d, J = 8.2 Hz, 1H, CH); δC (100 
MHz, d-CDCl3) 21.4, 26.2, 27.0, 34.6, 40.0, 44.4, 49.6, 53.0, 67.2, 70.9, 110.3, 114.1, 120.3, 124.7, 127.1, 
127.1, 127.3, 128.0, 128.2, 128.4, 128.5, 128.7, 128.7, 128.8, 129.1, 133.3, 133.8, 133.9, 135.8, 135.8, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8f (20.4 mg, 66 %); δH 
(400 MHz, d-CDCl3) 1.30-1.48 (m, 5H, CH2), 1.71-1.92 (m, 5H, CH2), 2.41-2.52 (m, 1H, CH), 2.52 (s, 3H, 
CH3), 3.83 (s, 2H, CH2), 4.71 (s, 2H, CH2), 4.76 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.45 (s, 
1H, CH), 6.62 (d, J = 8.1 Hz, 1H, CH), 7.98 (d, J = 8.0 Hz, 2H, CH), 7.11 (d, J = 8.0 Hz, 2H, CH), 7.24-7.41 
(m, 12H, CH), 7.45 (t, J = 6.8 Hz, 1H, CH), 7.82 (d, J = 8.1 Hz, 1H, CH), 7.96 (d, J = 7.8 Hz, 1H, CH); δC 
(100 MHz, d-CDCl3) 20.4, 26.2, 27.0, 34.6, 39.5, 44.4, 48.9, 53.0, 67.2, 70.9, 114.0, 120.2, 121.3, 125.9, 
127.1, 127.2, 128.2, 128.4, 128.5, 128.7, 128.8, 129.2, 129.3, 130.3, 132.7, 133.2, 133.4, 133.9, 135.8, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8g (19.8 mg, 52 %); 
δH (400 MHz, d-CDCl3) 1.32-1.48 (m, 5H, CH2), 1.70-1.95 (m, 5H, CH2), 2.36-2.61 (m, 1H, CH), 3.87 (s, 
2H, CH2), 4.64 (s, 2H, CH2), 4.71 (s, 2H, CH2), 4.92 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.48 (s, 1H, CH), 6.67 
(d, J = 8.1 Hz, 1H, CH), 6.98 (d, J = 7.7 Hz, 2H, CH), 7.12 (d, J = 7.7 Hz, 2H, CH), 7.30-7.48 (m, 10H, 
CH), 7.66 (t, 1H, CH), 7.86 (t,2H, CH), 7.92 (d, J = 8.0 Hz, 1H, CH), 8.09 (s, 1H, CH); δC (100 MHz, d-
CDCl3) 26.2, 27.0, 34.6, 39.9, 44.4, 49.6, 53.0, 67.3, 70.9, 114.0, 120.2, 121.5, 124.9, 127.2, 127.3, 128.3, 
128.4, 128.5, 128.7, 128.8, 129.1, 129.8, 131.1, 133.4, 133.7, 135.7, 135.8, 140.7, 144.5, 148.1, 159.0, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8h (29.8 mg, 94 %); 
δH (400 MHz, d-CDCl3) 1.27 (d, J = 7.6 Hz, 6H, CH3), 1.32-1.49 (m, 5H, CH2), 1.70-1.92 (m, 5H, CH2), 
2.42-2.55 (m, 1H, CH), 2.98 (m, 1H, CH), 3.88 (s, 2H, CH2), 4.65 (s, 2H, CH2), 4.76 (s, 2H, CH2), 4.94 (s, 
2H, CH2), 5.37 (s, 2H, CH2), 6.54 (s, 1H, CH), 6.70 (d, J = 8.0 Hz, 1H, CH), 7.03 (d, J = 8.0 Hz, 2H, CH), 
7.14 (d, J = 8.0 Hz, 2H, CH), 7.28-7.43 (m, 12H, CH), 7.69 (d, J = 8.0 Hz, 2H, CH), 7.86 (d, J = 8.0 Hz, 1H, 
CH); δC (100 MHz, d-CDCl3) 23.7, 26.2, 26.9, 34.3, 34.6, 40.0, 44.4, 49.7, 53.0, 67.2, 70.8, 110.3, 114.1, 
120.3, 127.0, 127.1, 127.2, 127.8, 128.2, 128.4, 128.4, 128.7, 128.7, 129.1, 133.3, 133.9, 135.8, 136.9, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8i (25.9 mg, 94 %); δH 
(400 MHz, d-CDCl3) 127.9 (t, J = 7.8 Hz, 3H, CH3), 1.32-1.52 (m, 5H, CH2), 1.68-1.93 (m, 5H, CH2), 2.38-
2.57 (m, 1H, CH), 2.73 (q, J = 7.8 Hz, 2H, CH2), 3.86 (s, 2H, CH2), 4.64 (s, 2H, CH2), 4.75 (s, 2H, CH2), 
4.93 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.53 (s, 1H, CH), 6.69 (d, J = 8.1 Hz, 1H, CH), 7.01 (d, J = 7.3 Hz, 2H, 
CH), 7.13 (d, J = 7.3 Hz, 2H, CH), 7.31-7.45 (m, 10H, CH), 7.69 (d, J = 7.5 Hz, 2H, CH), 7.85 (d, J = 8.1 
Hz, 1H, CH); δC (100 MHz, d-CDCl3) 15.2, 26.2, 27.0, 29.0, 34.6, 40.0, 44.4, 49.6, 53.0, 67.2, 70.9, 114.1, 
120.3, 121.2, 127.1, 127.3, 127.8, 128.2, 128.4, 128.4, 128.7, 128.7, 129.1, 133.3, 133.9, 135.8, 136.7, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8j (19.3 mg, 66 %); δH 
(400 MHz, d-CDCl3) 1.31-1.48 (m, 5H, CH2), 1.68-1.94 (m, 5H, CH2), 2.29 (s, 3H, CH3), 2.41-2.51 (m, 1H, 
CH), 2.53 (s, 6H, CH3), 3.79 (s, 2H, CH2), 4.68 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.35 (s, 
2H, CH2), 6.46 (s, 1H, CH), 6.57 (d, J = 8.0 Hz, 1H, CH), 6.90 (s, 2H, CH), 6.98 (d, J = 7.8 Hz, 2H, CH), 
7.11 (d, J = 7.8 Hz, 2H, CH), 7.27-7.44 (m, 10H, CH), 7.81 (d, J = 8.1 Hz, 1H, CH); δC (100 MHz, d-
CDCl3) 21.0, 22.9, 26.2, 27.0, 34.6, 39.1, 44.4, 48.7, 53.0, 67.2, 70.8, 113.9, 120.2, 121.1, 127.1, 127.3, 
128.2, 128.4, 128.5, 128.7, 128.7, 129.1, 131.9, 132.5, 133.2, 133.3, 134.0, 135.8, 135.8, 140.9, 143.1, 








Amine 7 was functionalized on a 0.04 mmol scale using General Procedure A to give 8k (20.3 mg, 52 %); 
δH (400 MHz, d-CDCl3) 1.32-1.48 (m, 5H, CH2), 1.70-1.93(m, 5H, CH2), 2.38-2.59 (m, 1H, CH), 3.86 (s, 
2H, CH2), 4.71(s, 2H, CH2), 4.74 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.34 (s, 2H, CH2), 6.46 (s, 1H, CH), 6.64 
(d, J = 8.1 Hz, 1H, CH), 6.97 (d, J = 7.6 Hz, 2H, CH), 7.11 (d, J = 7.4 Hz, 2H, CH), 7.25-7.44 (m, 10H, 
CH), 7.65-7.76 (m, 2H, CH), 7.82 (d, J = 7.9 Hz, 1H, CH), 7.86-7.94 (m, 1H, CH), 8.23-8.36 (m, 1H, CH); 
δC (100 MHz, d-CDCl3) 26.1, 26.8, 34.5, 39.5, 44.3, 49.1, 53.0, 67.1, 70.8, 109.4, 113.9, 120.0, 121.2, 
127.0, 127.1, 128.1, 128.2, 128.3, 128.6, 128.6, 129.0, 132.0, 132.1, 132.7, 133.2, 133.2, 133.7, 135.7, 






Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8l (24.7 mg, 84 %); δH 
(400 MHz, d-CDCl3) 1.32-1.48 (m, 5H, CH2), 1.70-1.92 (m, 5H, CH2), 2.41-2.57 (m, 1H, CH), 3.85 (s, 2H, 
CH2), 4.62 (s, 2H, CH2), 4.71 (s, 2H, CH2), 4.92 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.48 (s, 1H, CH), 6.66 (d, J 
= 8.1 Hz, 1H, CH), 6.97 (d, J = 7.8 Hz, 1H, CH), 7.13 (d, J = 8.0 Hz, 2H, CH), 7.29-7.41 (m, 10H, CH), 
7.45 (d, J = 8.4 Hz, 2H, CH), 7.74 (d, J = 8.5 Hz, 2H, CH), 7.84 (d, J = 8.1 Hz, 1H, CH); δC (100 MHz, d-
CDCl3) 26.2, 26.9, 34.6, 39.9, 44.4, 49.4, 53.1, 67.3, 70.9, 114.0, 120.2, 121.4, 127.2, 127.2, 128.2, 128.4, 
128.5, 128.7, 128.8, 129.1, 129.3, 129.3, 133.4, 133.8, 135.8, 135.8, 137.9, 139.6, 144.7, 148.1, 159.0, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8m (14.9 mg, 58 %); 
δH (400 MHz, d-CDCl3) 1.36-1.45 (m, 5H, CH2), 1.70-1.91 (m, 5H, CH2), 2.40-2.56 (m, 1H, CH), 3.86 (s, 
2H, CH2), 4.61 (s, 2H, CH2), 4.69 (s, 2H, CH2), 4.92 (s, 2H, CH2), 5.31 (s, 2H, CH2), 6.47 (s, 1H, CH), 6.66 
(d, J = 7.4 Hz, 1H, CH), 7.95 (d, J = 8.0 Hz, 1H, CH), 7.14 (d, J = 8.0 Hz, 2H, CH), 7.28-7.43 (m, 10H, 
CH), 7.76 (d, J = 8.2 Hz, 2H, CH), 7.84 (d, J = 7.4 Hz, 1H, CH), 7.92 (d, J = 8.2 Hz, 2H, CH); δC (100 MHz, 
d-CDCl3) 25.6, 26.7, 34.5, 39.7, 44.2, 49.3, 50.8, 67.2, 70.8, 113.8, 116.6, 117.4, 120.0, 121.4, 127.0, 128.2, 








Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8n (30.2 mg, 100 %); 
δH (400 MHz, d-CDCl3) 1.36-1.52 (m, 5H, CH2), 1.69-1.93 (m, 5H, CH2), 2.40-2.60 (m, 1H, CH), 3.86 (s, 
2H, CH2), 4.62 (s, 2H, CH2), 4.72 (s, 2H, CH2), 4.93 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.49 (s, 1H, CH), 6.67 
(d, J = 7.8 Hz, 1H, CH), 6.97 (d, J = 7.92 Hz, 1H, CH), 7.09-7.21 (m, 4H, CH),7.30 – 7.48 (m, 9H, CH), 
7.79-7.91 (m, 3H, CH); δC (100 MHz, d-CDCl3) 26.2, 27.0, 34.6, 39.8, 44.4, 49.4, 53.1, 67.3, 70.9, 114.0, 
116.1, 116.3, 120.2, 127.2, 127.2, 128.3, 128.4, 128.5, 128.7, 128.8, 129.1, 130.6, 130.7, 133.4, 133.8, 








Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8o (27.8 mg, 97 %); 
δH (400 MHz, d-CDCl3) 1.35-1.49 (m, 5H, CH2), 1.70-1.94 (m, 5H, CH2), 2.40-2.57 (m, 1H, CH),3.85 (s, 
2H, CH2), 3.88 (s, 3H, CH3), 4.62 (s, 2H, CH2), 4.74 (s, 2H, CH2), 4.92 (s, 2H, CH2), 5.36 (s, 2H, CH2), 
6.51 (s, 1H, CH), 6.68 (d, J = 8.2 Hz, 1H, CH), 6.95 (d, J = 8.8 Hz, 2H, CH), 6.99 (d, J = 7.9 Hz, 2H, CH), 
7.13 (d, J = 7.8 Hz, 2H, CH), 7.29-7.44 (m, 10H, CH), 7.74 (d, J = 8.8 Hz, 2H, CH), 7.84 (d, J = 8.2 Hz, 1H, 
CH); δC (100 MHz, d-CDCl3) 26.2, 26.9, 29.8, 34.6, 39.9, 44.4, 49.5, 53.0, 55.7, 67.2, 70.6, 114.1, 120.3, 
121.2, 127.1, 127.3, 128.2, 128.4, 128.4, 128.7, 128.7, 129.1, 130.0, 130.9, 133.3, 133.9, 133.9, 135.8, 







Amine 7 was functionalized on a 0.04 mmol scale using General Procedure A to give 8p (24.8 mg, 75 %); 
δH (400 MHz, d-CDCl3) 1.33-1.47 (m, 5H, CH2), 1.71-1.92 (m, 5H, CH2), 2.45-2.57 (m, 1H, CH),3.88 (s, 
2H, CH2), 4.63 (s, 2H, CH3), 4.68 (s, 2H, CH2), 4.93 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.47 (s, 1H, CH), 6.66 
(d, J = 8.0 Hz, 1H, CH), 6.94 (d, J = 8.0 Hz, 2H, CH), 7.14 (d, J = 7.9 Hz, 2H, CH), 7.30-7.46 (m, 10H, 
CH), 7.85 (d, J = 8.2 Hz, 1H, CH), 8.00 (d, J = 8.7 Hz, 2H, CH), 8.34 (d, J = 8.8 Hz, 2H, CH); δC (100 MHz, 
d-CDCl3) 26.2, 27.0, 34.6, 39.9, 44.4, 49.4, 53.2, 67.3, 70.9, 113.9, 120.1, 121.7, 124.2, 127.2, 128.3, 128.5, 
128.5, 128.7, 128.8, 129.1, 129.2, 133.5, 133.6, 133.9, 135.7, 135.8, 144.4, 145.1, 148.3, 150.3, 159.1, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8q (24.8 mg, 85 %); 
δH (400 MHz, d-CDCl3) 1.32-1.48 (m, 5H, CH2), 1.71-1.89 (m, 5H, CH2), 2.40-2.52 (m, 1H, CH), 3.89 (s, 
2H, CH2), 4.71 (s, 2H, CH2), 4.74 (s, 2H, CH2), 4.94 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.52 (s, 1H, CH), 6.69 
(d, J = 8.2 Hz, 1H, CH), 7.98 (d, J = 8.0 Hz, 2H, CH), 7.07 (d, J = 8.0 Hz, 2H, CH), 7.27-7.43 (m, 12H, 
CH),7.45 (d, J = 7.2 Hz, 1H, CH), 7.51 (t, J = 7.6 Hz, 2H, CH), 7.63 (d, J = 7.2 Hz, 2H, CH), 7.69 (d, J = 8.4 
Hz, 2H, CH), 7.84-7.89 (m, 3H, CH); δC (100 MHz, d-CDCl3) 26.2, 27.0, 34.6, 40.0, 44.3, 49.4, 53.1, 67.2, 
70.9, 110.3, 114.1, 120.3, 121.2, 127.1, 127.2, 127.5, 127.6, 128.2, 128.3, 128.4, 128.5, 128.6, 128.7, 128.8, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8r (24.5 mg, 87 %); 
δH (400 MHz, d-CDCl3) 1.44-1.57 (m, 5H, CH2), 1.68-1.91 (m, 5H, CH2), 2.34 (s, 6H, CH3), 2.42-2.56 (m, 
1H, CH), 3.82 (s, 2H, CH2), 4.67 (s, 2H, CH2), 4.78 (s, 2H, CH2), 4.93 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.56 
(s, 1H, CH), 6.70 (d, J = 8.0 Hz, 1H, CH), 7.02 (d, J = 7.8 Hz, 2H, CH), 7.13 (d, J = 7.8 Hz, 2H, CH), 7.17 
(s, 1H, CH), 7.24-7.46 (m, 12H, CH), 7.84 (d, J = 8.0 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 21.1, 26.1, 
26.8, 34.6, 39.9, 44.2, 49.5, 52.8, 67.1, 70.8, 114.1, 120.2, 121.0, 124.9, 127.0, 127.2, 128.1, 128.3, 128.3, 








Amine 7 was functionalized on a 0.04 mmol scale using General Procedure A to give 8s (39.0 mg, 98 %); 
δH (400 MHz, d-CDCl3) 1.34-1.47 (m, 5H, CH2), 1.69-1.92 (m, 5H, CH2), 2.42-2.56 (m, 1H, CH), 3.82 (s, 
2H, CH2), , 4.72 (s, 2H, CH2), 4.79 (s, 2H, CH2), 4.87 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.52 (s, 1H, CH), 
6.60 (d, J = 8.1 Hz, 1H, CH), 7.02 (d, J = 7.4 Hz, 2H, CH), 7.10 (d, J = 7.4 Hz, 2H, CH), 7.15 (s, 2H, CH), 
7.26-7.42 (m, 10H, CH), 7.80 (d, J = 8.0 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 11.0, 14.0, 23.5, 24.8, 26.1, 
26.8, 29.7, 34.5, 44.2, 47.7, 52.9, 67.1, 68.2, 70.7, 113.9, 120.2, 120.8, 123.8, 126.9, 127.2, 128.0, 128.2, 








Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8t (28.0 mg, 97 %); δH 
(400 MHz, d-CDCl3) 1.34-1.46 (m, 5H, CH2), 1.72-1.89 (m, 5H, CH2), 2.41-2.54 (m, 1H, CH), 3.89 (s, 2H, 
CH2), 4.72 (s, 4H, 2 CH2), 4.92 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.52 (s, 1H, CH), 6.68 (d, J = 8.0 Hz, 1H, 
CH), 6.95 (d, J = 7.8 Hz, 2H, CH), 7.07 (d, J = 7.8 Hz, 2H, CH), 7.27-7.43 (m, 10H, CH), 7.57-7.76 (m, 4H, 
CH), 7.85 (d, J = 8.0 Hz, 1H, CH), 7.89-7.95 (m, 3H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.8, 34.5, 39.9, 
44.2, 49.4, 52.8, 67.1, 70.7, 114.0, 120.1, 121.1, 122.7, 127.0, 127.2, 127.5, 127.9. 128.1, 128.3, 128.3, 
128.6, 128.6, 128.9, 129.0, 129.2, 129.2, 129.7, 130.9, 131.9, 133.2, 133.7, 134.9, 135.6, 135.7, 136.2, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8u (15.1 mg, 48 %); 
δH (400 MHz, d-CDCl3) 1.30-1.43 (m, 5H, CH2), 1.67-1.86 (m, 5H, CH2), 2.40-2.51 (m, 1H, CH), 4.00 (s, 
2H, CH2), 4.71 (s, 4H, 2 CH2), 4.74 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.52 (s, 1H, CH), 6.68 (d, J = 8.2 Hz, 
1H, CH), 6.98 (d, J = 8.0 Hz, 2H, CH), 7.09 (d, J = 8.0 Hz, 2H, CH), 7.27-7.41 (m, 10H, CH), 7.44-7.56 (m, 
3H, CH), 7.81-7.88 (m, 2H, CH), 7.99 (d, J = 8.2 Hz, 1H, CH), 8.25-8.35 (m, 2H, CH); δC (100 MHz, d-
CDCl3) 26.1, 26.8, 34.5, 39.9, 44.2, 49.6, 52.9, 67.1, 70.7, 114.0, 120.2, 121.0, 123.9, 124.4, 126.8, 127.0, 
127.1, 128.1, 128.2, 128.3, 128.4, 128.4, 128.6, 128.6, 128.7, 129.1, 130.6, 133.2, 133.8, 134.0, 134.2, 







Amine 7 was functionalized on a 0.03 mmol scale using General Procedure A to give 8v (23.4 mg, 76 %); 
δH (400 MHz, d-CDCl3) 1.28-1.43 (m, 5H, CH2), 1.67-1.86 (m, 5H, CH2), 2.39-2.51 (m, 1H, CH), 2.83 (s, 
6H, 2 CH3), 4.03 (s, 2H, CH2), 4.71 (s, 4H, 2 CH2), 4.77 (s, 2H, CH2), 4.89 (s, 2H, CH2), 5.35 (s, 2H, CH2), 
6.56 (s, 1H, CH), 6.70 (d, J = 8.2 Hz, 1H, CH), 7.01 (d, J = 8.0 Hz, 2H, CH), 7.06-7.12 (m, 3H, CH), 7.22-
7.47 (m, 12H, CH), 7.84 (d, J = 8.2 Hz, 1H, CH), 7.90 (d, J = 8.6 Hz, 1H, CH), 8.26 (d, J = 7.2 Hz, 1H, CH), 
8.46 (d, J = 8.5 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.8, 34.5, 39.9, 44.2, 45.3, 49.8, 53.0, 67.1, 
70.7, 114.0, 115.1, 118.8, 120.2, 120.9, 122.9, 127.0, 127.2, 128.0, 128.2, 128.3, 128.4, 128.6, 128.6, 129.1, 








10a, methyl 2-(4-fluoro-N-methylphenylsulfonamido)acetate 
Sarcosine methyl ester hydrochloride was functionalized on a 0.7 mmol scale using General Procedure A to 
give 10a (136 mg, 73 %); δH (400 MHz, d-CDCl3) 2.85 (s, 3H, CH3), 3.60 (s, 3H, CH3), 3.96 (s, 2H, CH2), 
7.16 (d, J = 8.4 Hz, 2H CH), 7.79 (d, J = 8.4 Hz, 2H, CH); ); δC (100 MHz, d-CDCl3) 35.4, 50.6, 52.0, 116.1 
(d), 129.9 (d), 134.3 (d), 165.0 (d), 168.7. 
 
 
10b, methyl 2-(N-methyl-4-(trifluoromethyl)phenylsulfonamido)acetate  
Sarcosine methyl ester hydrochloride was functionalized on a 0.7 mmol scale using General Procedure A to 
give 10b (189 mg, 84 %); δH (400 MHz, d-CDCl3) 2.89 (s, 3H, CH3), 3.59 (s, 3H, CH3), 4.01 (s, 2H, CH2), 
7.75 (d, J = 8.2 Hz, 2H CH), 7.92 (d, J = 8.2 Hz, 2H, CH); ); δC (100 MHz, d-CDCl3) 35.4, 50.6, 52.0, 123.1 







Secondary aniline 4 and carboxylic acid 11a were combined according to General Procedure E to give 12a 
(164 mg, 43 %); δH (400 MHz, d-CDCl3) 1.33-1.42 (m, 5H, CH2), 1.70-1.86 (m, 5H, CH2), 2.42-2.52 (m, 
1H, CH), 2.84 (s, 3H, CH3), 3.71 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.95 (s, 2H, CH2), 5.35 (s, 2H, CH2), 6.49 
(s, 1H, CH), 6.67 (dd, J = 8.4 and 1.6 Hz, 1H, CH), 7.00 (d, J = 8.0 Hz, 2H, CH), 7.10-7.15 (m, 4H, CH), 
7.29-7.38 (m, 8H, CH), 7.39-7.41 (m, 2H, CH), 7.75-7.79 (m, 2H, CH), 7.84 (d, J = 8.0 Hz, 1H, CH); δC 
(100 MHz, d-CDCl3) 26.0, 26.7, 34.4, 35.8, 44.1, 51.3, 52.8, 67.0, 70.6, 114.1, 115.5, 116.1, 120.0, 120.8, 
126.9, 127.0, 128.0, 128.2, 128.2, 128.5, 128.5, 128.8, 130.1, 130.2, 133.1, 133.8, 134.7, 135.7, 135.7, 








Secondary aniline 4 and carboxylic acid 11b were combined according to General Procedure E to give 12b 
(211 mg, 42 %); δH (400 MHz, d-CDCl3) 1.29-1.48 (m, 5H, CH2), 1.71-1.94 (m, 5H, CH2), 2.45-2.57 (m, 
1H, CH), 2.90 (s, 3H, CH3), 3.78 (s, 2H, CH2), 4.76 (s, 2H, CH2), 4.99 (s, 2H, CH2), 5.38 (s, 2H, CH2), 6.55 
(s, 1H, CH), 6.67 (d of d, J = 8.2 and 1.2 Hz, 1H, CH), 7.03 (d, J = 8.0 Hz, 2H, CH), 7.14 (d, J = 8.0 Hz, 
2H, CH), 7.27-7.47 (m, 10, CH), 7.75 (d, J = 8.4 Hz, 2H, CH), 7.87 (d, J = 8.2 Hz, 1H, CH), 7.92 (d, J = 8.2 
Hz, 2H, CH); δC (100 MHz, d-CDCl3) 26.0, 26.7, 34.4, 35.8, 44.1, 51.3, 52.8, 67.0, 70.6, 114.1, 120.0, 123.3 
(q), 128.5 (q), 126.9, 127.0, 127.9, 128.0, 128.1, 128.2, 128.3, 128.3, 128.5, 128.5, 128.8, 133.1, 133.8, 







Primary amine 6 was functionalized on a 0.3 mmol scale using General Procedure B to give 14a (97.4, 48 
%); δH (400 MHz, d-CDCl3) 1.26-1.46 (m, 5H, CH2), 1.69-1.90 (m, 5H, CH2), 2.41-2.54 (m, 1H, CH), 3.43 
(d, J = 3.8 Hz, 2H, CH2), 4.71 (s, 2H, CH2), 4.89 (s, 2H, CH2), 5.36 (s, 2H, CH2), 5.91 (t, J = 4.6 Hz, 1H, 
NH), 6.40 (s, 1H, CH), 6.52 (d, J = 8.0 Hz, 1H, CH), 6.92 (d, J = 8.0 Hz, 2H, CH), 7.07-7.16 (m, 4H, CH), 
7.31-7.44 (m, 10, CH), 7.76-7.85 (m, 3H, CH); δC (100 MHz, d-CDCl3) 25.9, 26.7, 34.3, 44.1, 44.2, 53.0, 
67.0, 70.7, 113.8, 116.1 (d), 119.8, 121.2, 126.9, 128.0, 128.2, 128.2, 128.5, 128.8, 129.8, 129.9, 131.2, 








Primary amine 6 was functionalized on a 0.28 mmol scale using General Procedure B to give 14b (155.4 
mg, 72 %); δH (400 MHz, d-CDCl3) 1.30-1.44 (m, 5H, CH2), 1.71-1.89 (m, 5H, CH2), 2.40-2.54 (m, 1H, 
CH), 3.49 (s (br), 2H, CH2), 4.74 (s, 2H, CH2), 4.90 (s, 2H, CH2), 5.36 (s, 2H, CH2), 6.18 (s (br), 1H, NH), 
6.44 (s, 1H, CH), 6.56 (d, J = 8.0 Hz, 1H, CH), 6.95 (d, J = 7.4 Hz, 2H, CH), 7.10 (d, J = 8.0 Hz, 2H, CH), 
7.30-7.44 (m, 10, CH), 7.73 (d, J = 8.2 Hz, 2H, CH), 7.82 (d, J = 8.2 Hz, 1H, CH), 7.93 (d, J = 8.2 Hz, 2H, 
CH); δC (100 MHz, d-CDCl3) 25.9, 26.7, 34.3, 44.1, 44.2, 53.0, 67.0, 70.7, 113.8, 119.8, 121.3, 123.2 (q), 
126.0 (q), 126.9, 127.6, 128.0, 128.2, 128.2, 128.5, 128.5, 128.8, 133.2, 133.2, 134.0, 134.3, 135.4, 135.5, 







Sulfonamide 14b was functionalized on a 0.06 mmol scale using General Procedure D to give 15c (46.3 mg, 
85 %); δH (400MHz, d-CHCl3) 1.30-1.45 (m, 5H, CH2), 1.70-1.86 (m, 5H, CH2), 2.40-2.55 (m, 1H, CH), 
3.71 (s, 2H, CH2), 4.66 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.79 (s, 2H, CH2), 5.31 (s, 2H, CH2), 6.34 (s, 1H, 
CH), 6.48 (d, J = 8.0 Hz, 1H, CH), 6.92 (d, J = 8.0 Hz, 2H, CH), 7.09 (d, J = 8.0 Hz, 2H, CH), 7.13-7.20 (m, 
3H, CH), 7.27-7.39 (m, 12H, CH), 7.49 (t, J = 7.6 Hz, 1H, CH), 7.60 (d, J = 7.8 Hz, 1H, CH), 7.66-7.77 (m, 
2H, CH), 7.85-7.92 (m, 2H, CH); δC (100MHz, d-CHCl3) 25.9, 26.7, 34.3, 44.1, 47.4, 47.7, 52.7, 66.9, 70.5, 
113.7, 115.9 (d), 119.8, 120.8, 122.6, 125.5 (d), 126.8, 126.9, 127.7, 127.9, 128.1, 128.2, 128.3, 128.4, 
128.4, 128.8, 129.8, 130.3, 130.4, 132.4, 133.0, 133.6, 134.5, 135.5, 135.5, 135.6, 135.7, 144.6, 147.7, 







Sulfonamide 14b was functionalized on a 0.08 mmol scale using General Procedure D to give 15d (47.1 mg, 
73 %); δH (400MHz, d-CHCl3) 1.30-1.48 (m, 5H, CH2), 1.71-1.92 (m, 5H, CH2), 2.23 (s, 3H, CH3), 2.44-
2.55 (m, 1H, CH), 3.61 (s, 2H, CH2), 4.59 (s, 2H, CH2), 4.64 (s, 2H, CH2), 4.75 (s, 2H, CH2), 5.32 (s, 2H, 
CH2), 6.19 (s, 1H, CH), 6.32 (d, J = 7.8 Hz, 1H, CH), 6.96 (d, J = 8.0 Hz, 2H, CH), 7.05 (d, J = 7.2 Hz, 1H, 
CH), 7.09-7.21 (m, 7H CH), 7.30-7.39 (m, 10H, CH), 7.69 (d, J = 8.0 Hz, 1H, CH), 7.87-7.94 (m, 2H, CH); 
δC (100MHz, d-CHCl3) 18.9, 25.9, 26.7, 34.4, 44.1, 46.7, 49.0, 52.6, 66.9, 70.6, 113.6, 115.9 (d), 119.9, 
120.7, 125.9, 126.8, 127.0, 128.0, 128.1, 128.2, 128.2, 128.9, 129.9, 129.9, 130.2, 130.3, 130.7, 132.4, 







Sulfonamide 14d was functionalized on a 0.09 mmol scale using General Procedure D to give 15g (65.4 mg, 
81 %); δH (400 MHz, d-CDCl3) 1.30-1.46 (m, 5H, CH2), 1.71-1.89 (m, 5H, CH2), 2.42-2.53 (m, 1H, CH), 
3.73 (s, 2H, CH2), 4.65 (s, 2H, CH2), 4.76 (s, 2H, CH2), 4.79 (s, 2H, CH2), 5.32 (s, 2H, CH2), 6.34 (s, 1H, 
CH), 6.48 (d, J = 8.0 Hz, 1H, CH), 6.92 (d, J = 8.0 Hz, 2H, CH), 7.09 (d, J = 8.0 Hz, 2H, CH), 7.27-7.40 (m, 
11H, CH), 7.50 (t, J = 7.6 Hz, 1H, CH), 7.60 (d, J = 7.8 Hz, 1H, CH), 7.69 (d, J = 7.8 Hz, 1H, CH), 7.72 (d, 
J = 8.0 Hz, 1H, CH), 7.78 (d, J = 8.2 Hz, 2H, CH), 8.00 (d, J = 8.2 Hz, 2H, CH); δC (100 MHz, d-CDCl3) 
25.9, 26.7, 34.3, 44.0, 47.4, 47.8, 52.7, 66.9, 70.6, 113.7, 119.8, 120.8, 125.5, 125.6, 125.8, 125.8, 126.8, 
126.9, 127.8, 128.0, 128.1, 128.2, 128.4, 128.8, 129.9, 132.4, 133.0, 133.6, 134.0, 134.1, 134.3, 135.5, 







Sulfonamide 14d was functionalized on a 0.10 mmol scale using General Procedure D to give 15h (79.7 mg, 
93 %); δH (400 MHz, d-CDCl3) 1.30-1.47 (m, 5H, CH2), 1.70-1.90 (m, 5H, CH2), 2.22 (s, 3H, CH3), 2.42-
2.54 (m, 1H, CH), 3.61 (s, 2H, CH2), 4.46 (s, 2H, CH2), 4.61 (s, 2H, CH2), 4.74 (s, 2H, CH2), 5.30 (s, 2H, 
CH2), 6.17 (s, 1H, CH), 6.30 (d, J = 8.0 Hz, 1H, CH), 6.93 (d, J = 8.0 Hz, 2H, CH), 7.02-7.19 (m, 6H, CH), 
7.29-7.37 (m, 10H, CH), 7.68 (d, J = 8.0 Hz, 1H, CH), 7.77 (d, J = 8.2 Hz, 2H, CH), 7.99 (d, J = 8.2 Hz, 2H 
CH); δC (100 MHz, d-CDCl3) 18.8, 25.9, 26.7, 34.3, 44.1, 46.8, 49.0, 52.6, 66.9, 70.6, 113.6, 119.9, 120.8, 
124.6, 125.7, 125.8, 125.9, 126.8, 127.0, 128.0, 128.1, 128.2, 128.3, 128.4, 128.5, 128.9, 129.9, 130.7, 













δH (400 MHz, d-CDCl3) 1.34-1.50 (m, 5H, CH2), 1.68-1.93 (m, 5H, CH2), 2.39-2.57 (m, 1H, CH), 3.96 (s, 
2H, CH2), 4.67 (s, 2H, CH2), 4.72 (s, 2H, CH2), 6.50 (s (br), 1H, CH), 6.64 (s, 1H, CH), 6.99 (d, J = 7.8 Hz, 
2H, CH), 7.09 (d, J = 7.8 Hz, 2H, CH), 7.47 (t, J = 7.2 Hz, 2H, CH), 7.58 (t, J = 7.1 Hz, 1H, CH), 7.82 (d, J 
= 6.8 Hz, 2H, CH), 7.88 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 26.0, 26.7, 34.2, 39.7, 44.1, 49.2, 52.9, 
110.0, 116.6, 118.3, 125.4, 126.8, 127.4, 128.4, 128.7, 132.8, 133.4, 136.0, 139.0, 147.5, 155.9, 162.8, 
166.4. HRMS (ESI) Calcd for [C35H31F5N2O6S + H] 703.1895 found 703.1927; HPLC (I) tR = 25.06 min 







δH (400 MHz, d-CDCl3) 1.32-1.53 (m, 5H, CH2), 1.68-1.97 (m, 5H, CH2), 2.35-2.57 (m, 1H, CH), 3.15 (s, 
3H, C3), 3.89 (s, 2H, CH2), 4.63 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.46(s (br), 1H, CH), 6.60 (s, 1H, 
CH),6.92-7.19 (m, 4H, CH), 7.83 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 26.2, 27.0, 34.5, 39.4, 40.6, 
44.3, 49.6, 53.3, 112.3, 118.6, 119.9, 125.6, 127.1, 127.2, 128.4, 128.5, 133.4, 136.4, 138.8, 148.0, 159.2, 
167.2, 169.3. HRMS (ESI) Calcd for [C30H29F5N2O6S + H] 641.1739 found 641.1748; HPLC (I) tR = 24.25 









δH (400 MHz, d-CDCl3) 1.31-1.42 (m, 5H, CH2), 1.70-1.92 (m, 5H, CH2), 2.41-2.55 (m, 1H, CH), 4.00 (s, 
2H, CH2), 4.67 (s, 2H, CH2), 4.73 (s, 2H, CH2), 6.55 (s (br), 1H, CH), 6.69 (s, 1H, CH), 7.01 (d, J = 7.6 Hz, 
2H, CH), 7.12 (d, J = 7.6 Hz, 2H, CH), 7.77 (d, J = 7.8 Hz, 2H, CH), 7.98 (m, 3H, CH); δC (100 MHz, d-
CDCl3) 26.3, 27.0, 34.5, 40.0, 44.4, 49.5, 53.3, 113.4, 117.6, 120.4, 122.1, 122.2, 125.7, 126.2, 127.2, 
128.4, 128.7, 128.7, 133.5, 142.8, 148.0, 158.6, 163.0, 165.8. HRMS (ESI) Calcd for [C36H30F8N2O6S + H] 









δH (400 MHz, d-CDCl3) 1.36-1.47 (m, 5H, CH2), 1.69-1.94 (m, 5H, CH2), 2.39-2.55 (m, 1H, CH), 4.00 (s, 
2H, CH2), 4.67 (s, 2H, CH2), 4.79 (s, 2H, CH2), 6.58 (d, J = 6.9 Hz, 1H, CH), 6.70 (s, 1H, CH), 7.05 (d, J = 
7.8 Hz, 2H, CH), 7.12 (d, J = 7.8 Hz, 2H, CH), 7.49 (d, J = 8.2 Hz, 2H, CH), 7.73 (d, J = 8.1 Hz, 2H, CH), 
7.91 (s,1H, CH); δC (100 MHz, d-CDCl3) 26.3, 27.0, 31.2, 34.5, 35.3, 40.1, 44.4, 49.9, 53.2, 110.2, 117.2, 
119.0, 125.9, 127.2, 127.6, 128.6, 132.5, 133.6, 133.9, 136.3, 138.8, 147.9, 157.0, 163.1, 166.9. HRMS 
(ESI) Calcd for [C39H39F5N2O6S + H] 759.2521 found 759.2551; HPLC (I) tR = 27.38 min (97.1 %), (II) tR 








δH (400 MHz, d-CDCl3) 1.31-1.43 (m, 5H, CH2), 1.70-1.91 (m, 5H, CH2), 2.39 (s, 3H, CH3), 2.40-2.54 (m, 
1H, CH), 3.96 (s, 2H, CH2), 4.66 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.55 (s (br), 1H, CH), 6.68 (s, 1H, CH), 
7.00 (d, J = 6.8 Hz, 2H, CH), 7.10 (d, J = 6.8 Hz, 2H, CH), 7.31-7.43 (m, 2H, CH), 7.56-7.68 (m, 2H, CH), 
7.90 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 21.1, 26.0, 26.7, 34.2, 39.7, 44.1, 49.3, 53.0, 109.8, 116.2, 
118.5, 123.0, 124.6, 125.4, 126.9, 127.8, 128.3, 128.6, 132.4, 133.3, 133.7, 146.8, 147.6, 159.1, 162.8, 
166.7. HRMS (ESI) Calcd for [C36H33F5N2O6S + H] 717.2052 found 717.2087; HPLC (I) tR = 25.56 min 








δH (400 MHz, d-CDCl3) 1.30-1.42 (m, 5H, CH2), 1.70-1.91 (m, 5H, CH2), 2.40-2.52 (m, 1H, CH), 2.54 (s, 
3H, CH3), 3.93 (s, 2H, CH2), 4.73 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.48 (s (br), 1H, CH), 6.61 (s, 1H, CH), 
7.00 (d, J = 7.2 Hz, 2H, CH), 7.09 (d, J = 7.2 Hz, 2H, CH), 7.27-7.32 (m, 2H, CH), 7.46 (t, J = 7.2 Hz, 1H, 
CH), 7.88 (s (br), 1H, CH), 7.99, d, (J = 7.4 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 20.1, 26.0, 26.7, 34.2, 
39.2, 44.0, 48.6, 52.9, 112.2, 118.0, 118.6, 125.7, 126.8, 128.5, 130.2, 132.5, 133.1, 133.2, 136.8, 138.3, 
140.2, 144.2, 147.6, 158.9, 162.9, 166.1. HRMS (ESI) Calcd for [C36H33F5N2O6S + H] 717.2052 found 








δH (400 MHz, d-CDCl3) 1.29-1.45 (m, 5H, CH2), 1.65-1.93 (m, 5H, CH2), 2.36-2.54 (m, 1H, CH), 3.98 (s, 
2H, CH2), 4.64 (s, 2H, CH2), 4.72 (s, 2H, CH2), 6.53 (s (br), 1H, CH), 6.64 (s, 1H, CH), 7.99 (d, J = 7.2 Hz, 
2H, CH), 7.06 (d, J = 7.2 Hz, 2H, CH), 7.62 (t, J = 7.0 Hz, 1H, CH), 7.82 (d, J = 7.0 Hz, 1H, CH), 7.90 (s 
(br), 1H, CH), 8.04 (d, J = 7.2 Hz, 1H, CH), 8.07, (s, 1H, CH); HRMS (ESI) Calcd for [C36H30F8N2O6S + 










δH (400 MHz, d-CDCl3) 1.31-1.47 (m, 5H, CH2), 1.68-1.92 (m, 5H, CH2), 2.35-2.55 (m, 1H, CH), 2.86-3.04 
(m, 1H, CH), 3.98 (s, 2H, CH2), 4.65 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.56 (d, J = 5.5 Hz, 1H, CH), 6.68 (s, 
1H, CH), 7.03 (d, J = 7.5 Hz, 1H, CH), 7.10 (d, J = 7.5 Hz, 2H, CH), 7.31 (d, J = 8.0 Hz, 2H, CH), 7.72 (d, J 
= 7.9 Hz, 2H, CH), 7.88 (d, J = 6.0 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 14.1, 23.6, 26.1, 26.9, 34.2, 34.4, 
39.0, 44.2, 49.6, 53.1, 110.1, 117.0, 118.9, 125.5, 126.9, 127.0, 127.8, 128.5, 132.4, 133.4, 136.1, 136.4, 
147.8, 154.6, 163.0, 166.8, 172.7. HRMS (ESI) Calcd for [C38H37F5N2O6S + H] 745.2365 found 745.2341; 








δH (400 MHz, d-CDCl3) 1.25 (t, J = 7.2 Hz, 3H, CH3), 1.33-1.51 (m, 5H, CH2), 1.67-1.96 (m, 5H, CH2), 
2.40-2.57 (m, 1H, CH), 2.72 (q, J = 7.2 Hz, 2H, CH2), 3.97 (s, 2H, CH2), 4.65 (s, 2H, CH2), 4.75 (s, 2H, 
CH2), 6.56 (s (br), 1H, CH), 6.67 (s, 1H, CH), 7.02 (d, J = 7.5 Hz, 2H, CH), 7.10 (d, J = 7.5 Hz, 2H, CH), 
7.29 (d, J = 7.8 Hz, 2H, CH), 7.71 (d, J = 7.7 Hz, 2H, CH), 7.86 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 
15.2, 26.3, 27.0, 29.8, 34.5, 40.0, 44.4, 49.6, 53.2, 112.8, 117.2, 119.0, 125.7, 127.1, 127.9, 128.5, 128.6, 
132.6, 133.6, 136.4, 147.9, 150.2, 163.1, 166.9. HRMS (ESI) Calcd for [C37H35F5N2O6S + H] 731.2208 








δH (400 MHz, d-CDCl3) 1.29-1.41 (m, 5H, CH2), 1.67-1.91 (m, 5H, CH2), 2.28 (s, 3H, CH3), 2.38-2.48 (m, 
1H, CH), 2.52 (s, 6H, CH3), 3.82 (s, 2H, CH2), 4.72 (s, 2H, CH2), 4.74 (s, 2H, CH2), 6.41 (s, 1H, CH), 6.51 
(s, 1H, CH), 6.91 (s, 2H, CH), 6.97 (d, J = 6.2 Hz, 2H, CH), 7.07 (d, J = 7.4 Hz, 2H, CH), 7.76-7.92 (m, 1H, 
CH); δC (100 MHz, d-CDCl3) 20.9, 22.7, 26.1, 26.9, 34.4, 38.9, 44.2, 48.3, 53.0, 107.2, 109.7, 117.1, 125.7, 
127.1, 128.6, 128.6, 132.1, 132.1, 133.6, 141.0, 143.3, 147.3, 147.8, 163.1, 166.8. HRMS (ESI) Calcd for 






















(trifluoromethyl)phenylsulfonamido)acetamido)-2-hydroxybenzoic acid  
δH (400 MHz, d-CDCl3) 1.32-1.52 (m, 5H, CH2), 1.67-1.93 (m, 5H, CH2), 2.48-2.57 (m, 1H, CH), 3.91 (s, 
2H, CH2), 4.71 (s, 2H, CH2), 4.86 (s, 2H, CH2), 6.48 (s, 1H, CH), 6.59 (s, 1H, CH), 6.98 (d, J = 7.9 Hz, 2H, 
CH), 7.12 (d, J = 7.7 Hz, 2H, CH), 7.26 (s, 1H, OH), 7.29-7.40 (m, 1H, CH), 7.62-7.77 (m, 2H, CH), 7.83-
7.96 (m, 2H, CH) 8.22-8.39 (m, 1H, CH); δC (100 MHz, d-CDCl3) 26.3, 27.0, 34.5, 40.0, 44.4, 49.2, 53.1, 
109.5, 117.1, 118.9, 121.3, 124.0, 125.7, 126.5, 127.1, 127.2, 128.7, 128.8, 132.2, 132.3, 133.0, 133.5, 
138.7, 147.9, 163.0, 166.2. HRMS (ESI) Calcd for [C36H30F8N2O6S + H] 771.1769 found 771.1802; HPLC 








δH (400 MHz, d-CDCl3) 1.31-1.49 (m, 5H, CH2), 1.67-1.92 (m, 5H, CH2), 2.38-2.55 (m, 1H, CH), 3.95 (s, 
2H, CH2), 4.65 (s, 2H, CH2), 4.74 (s, 2H, CH2), 6.53 (d, J = 6.8 Hz, 1H, CH), 6.65 (s, 1H, CH), 6.99 (d, J = 
7.4 Hz, 1H, CH), 7.12 (d, J = 7.4 Hz, 2H, CH), 7.46 (d, J = 8.0 Hz, 2H, CH), 7.78 (d, J = 8.0 Hz, 2H, CH), 
7.89 (d, J = 8.0 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.3, 27.0, 34.5, 40.0, 44.4, 49.4, 53.3, 112.3, 117.2, 
119.0, 126.5, 127.2, 127.7, 128.7, 129.0, 129.3, 132.6, 133.1, 133.4, 137.8, 139.7, 148.0, 163.2, 166.4, 
172.1. HRMS (ESI) Calcd for [C35H30ClF5N2O6S + H] 737.1506, found 737.1491; HPLC (I) tR = 27.78 min 








δH (400 MHz, d-CDCl3) 1.35-1.46 (m, 5H, CH2), 1.71-1.94 (m, 5H, CH2), 2.40-2.56 (m, 1H, CH), 3.96 (s, 
2H, CH2), 4.61 (s, 2H, CH2), 4.69 (s, 2H, CH2), 6.48 (s (br), 1H, CH), 6.62 (s, 1H, CH), 6.98 (d, J = 7.8 Hz, 
2H, CH), 7.11 (d, J = 7.8 Hz, 2H, CH), 7.71 (d, J = 8.0 Hz, 2H, CH), 7.89-7.98 (m, 3H, CH), 8.11 (s,1H, 
CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 39.9, 44.2, 49.4, 53.0, 110.2, 118.9, 122.3, 122.9, 127.0, 
127.7, 128.5, 129.5, 132.7, 133.4, 136.1, 143.9, 147.8, 156.4, 163.1, 166.6; HRMS (ESI) Calcd for 









δH (400 MHz, d-CDCl3) 1.28-1.46 (m, 5H, CH2), 1.68-1.90 (m, 5H, CH2), 2.38-2.52 (m, 1H, CH), 3.96 (s, 
2H, CH2), 4.61 (s, 2H, CH2), 4.72 (s, 2H, CH2), 6.51 (s (br), 1H, CH), 6.65 (s (br), 1H, CH), 6.99 (d, J = 7.2 
Hz, 2H, CH), 7.06-7.21 (m, 4H, CH), 7.78-7.95 (m, 3H, CH); HRMS (ESI) Calcd for [C35H30F6N2O6S + H] 
























δH (400 MHz, d-CDCl3) 1.35-1.49 (m, 5H, CH2), 1.70-1.94 (m, 5H, CH2), 2.40-2.57 (m, 1H, CH),3.64 (s, 
3H, CH3), 3.73 (s, 2H, CH2), 4.40 (s, 2H, CH2), 4.53 (s, 2H, CH2), 6.32 (s (br), 1H, CH), 6.44 (s, 1H, CH), 
6.71 (d, J = 7.6 Hz, 2H, CH), 6.79 (d, J = 8.0 Hz, 2H, CH), 6.89 (d, J = 8.0 Hz, 2H, CH), 7.54 (d, J = 7.6 Hz, 
2H, CH), 7.64 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 39.8, 44.2, 49.4, 53.0, 55.6, 
110.25, 114.1, 117.0, 118.9, 125.5, 127.0, 128.4, 128.8, 130.0, 130.5, 132.4, 133.4, 147.8, 163.2, 166.8, 
172.5. HRMS (ESI) Calcd for [C36H33F5N2O7S + H] 733.2001 found 733.1986; HPLC (I) tR = 24.97 min 








δH (400 MHz, d-CDCl3) 1.28-1.42 (m, 5H, CH2), 1.65-1.90 (m, 5H, CH2), 2.22-2.41 (m, 1H, CH),3.91 (s, 
2H, CH2), 4.63 (s, 2H, CH3), 4.66 (s, 2H, CH2), 6.46 (s (br), 1H, CH), 6.59 (s, 1H, CH), 6.86-7.00 (m, 4H, 
CH), 7.53 (d, J = 7.2 Hz, 2H, CH), 7.62 (d, J = 7.4 Hz, 2H, CH), 7.80 (s (br), 1H, CH); δC (100 MHz, d-
CDCl3) 26.7, 26.8, 34.4, 39.9, 44.2, 49.4, 53.1, 110.2, 117.0, 118.8, 126.9, 127.4, 127.5, 128.2, 128.5, 
129.0, 129.7, 133.4, 137.6, 139.3, 146.0, 147.7, 162.9, 167.9. HRMS (ESI) Calcd for [C35H32F5N3O6S + H] 








ylsulfonamido)acetamido)-2-hydroxybenzoic acid  
δH (400 MHz, d-CDCl3) 1.37-1.45 (m, 5H, CH2), 1.68-1.80 (m, 5H, CH2), 2.36-2.45 (m, 1H, CH), 3.91 (s, 
2H, CH2), 4.63 (s, 2H, CH2), 4.66 (s, 2H, CH2), 6.46 (s (br), 1H, CH), 6.59 (s, 1H, CH), 6.85-6.99 (m, 4H, 
CH),7.30-7.48 (m, 3H, CH), 7.53 (d, J = 7.2 Hz, 2H, CH), 7.61 (d, J = 8.0 Hz, 2H, CH), 7.81 (m, 3H, CH); 
HRMS (ESI) Calcd for [C41H35F5N2O6S + H] 779.2208 found 779.2190; HPLC (I) tR = 26.77 min (93.8 %), 










δH (400 MHz, d-CDCl3) 1.42-1.60 (m, 5H, CH2), 1.69-1.91 (m, 5H, CH2), 2.24 (s, 6H, CH3), 2.39-2.52 (m, 
1H, CH), 3.86 (s, 2H, CH2), 4.56 (s, 2H, CH2), 4.69 (s, 2H, CH2), 6.46 (s (br), 1H, CH), 6.59 (s, 1H, CH), 
6.91-7.05 (m, 4H, CH), 7.08 (s, 1H, CH), 7.29 (s, 2H, CH), 7.81 (s (br), 1H, CH); δC (100 MHz, d-CDCl3) 
21.1, 26.1, 26.8, 34.4, 39.9, 44.2, 49.5, 53.1, 110.1, 116.9, 118.7, 125.1, 127.0, 128.4, 128.4, 133.5, 134.7, 
138.6, 138.9, 146.9, 147.7, 162.9, 165.3, 167.0. HRMS (ESI) Calcd for [C37H35F5N2O6S + H] 731.2208 









δH (400 MHz, d-CDCl3) 1.29-1.46 (m, 5H, CH2), 1.70-1.92 (m, 5H, CH2), 2.41-2.52 (m, 1H, CH), 3.94 (s, 
2H, CH2),4.25-4.36 (m, 4H, 2 CH2), 4.66 (s, 2H, CH2), 4.78 (s, 2H, CH2), 6.58 (d, J = 8.2 Hz, 1H, CH), 6.68 
(s, 1H, CH), 6.92 (d, J = 8.4 Hz, 1H, CH), 7.03 (d, J = 8.0 Hz, 2H, CH), 7.11 (d, J = 8.0 Hz, 2H, CH), 7.27-
7.35 (m, 2H, CH), 7.88 (d, J = 8.4 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 40.0, 44.2, 49.4, 
53.0, 64.2, 64.6, 110.4, 117.2, 117.3, 117.6, 119.1, 121.4, 127.1, 128.5, 131.4, 132.5, 133.3, 143.4, 147.7, 
147.8, 163.0, 166.7, 172.7, 177.3; HRMS (ESI) Calcd for [C37H33F5N2O8S + H] 761.1950 found 761.1942; 








δH (400 MHz, d-CDCl3) 1.27-1.45 (m, 5H, CH2), 1.67-1.89 (m, 5H, CH2), 2.37-2.50 (m, 1H, CH), 4.00 (s, 
2H, CH2), 4.69 (s, 2H, CH2), 4.72 (s, 2H, CH2), 6.52 (d, J = 7.0 Hz, 1H, CH), 6.66 (s, 1H, CH), 6.83 (d, J = 
7.4 Hz, 2H, CH), 7.02 (d, J = 7.4 Hz, 2H, CH), 7.55-7.67 (m, 2H, CH), 7.74 (d, J = 8.5 Hz, 1H, CH), 7.84-
7.98 (m, 4H, CH), 8.38 (s, 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 40.0, 44.2, 49.4, 53.0, 110.1, 
116.9, 118.8, 122.7, 127.0, 127.5, 127.9, 128.4, 129.0, 129.1, 129.2, 131.9, 132.6, 133.4, 134.9, 135.9, 
144.3, 147.7, 162.9, 166.7, 173.3, 177.1; HRMS (ESI) Calcd for [C39H33F5N2O6S + H] 753.2052 found 








δH (400 MHz, d-CDCl3) 1.28-1.46 (m, 5H, CH2), 1.69-1.89 (m, 5H, CH2), 2.39-2.51 (m, 1H, CH), 4.12 (s, 
2H, CH2), 4.74 (s, 4H, 2 CH2), 6.56 (d, J = 8.0 Hz, 1H, CH), 6.67 (s, 1H, CH), 6.98 (d, J = 7.8 Hz, 2H, CH), 
7.09 (d, J = 7.8 Hz, 2H, CH), 7.46-7.61 (m, 3H, CH), 7.83-7.94 (m, 2H, CH), 8.02 (d, J = 8.2 Hz, 1H, CH), 
8.32 (d, J = 7.3 Hz, 1H, CH), 8.41 (d, J = 8.2 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 39.9, 
44.2, 49.6, 53.1, 109.9, 117.1, 119.1, 124.0, 124.4, 126.8, 127.0, 128.2, 128.5, 128.8, 130.7, 132.5, 133.3, 
134.0, 134.1, 134.7, 147.5, 147.7, 163.0, 166.6, 173.1, 177.3; HRMS (ESI) Calcd for [C39H33F5N2O6S + H] 








δH (400 MHz, d-CDCl3) 1.29-1.45 (m, 5H, CH2), 1.69-1.91 (m, 5H, CH2), 2.40-2.53 (m, 1H, CH),2.86 (s, 
6H, 2 CH3), 4.13 (s, 2H, CH2), 4.75 (s, 2H, CH2), 4.77 (s, 2H, CH2), 6.57 (d, J = 8.2 Hz, 1H, CH), 6.67 (s, 
1H, CH), 7.00 (d, J = 8.0 Hz, 2H, CH), 7.10 (d, J = 8.0 Hz, 2H, CH), 7.14 (d, J = 7.6 Hz, 1H, CH), 7.42-7.52 
(m, 2H, CH), 7.89 (d, J = 8.3 Hz, 1H, CH), 8.04 (d, J = 8.6 Hz, 1H, CH), 8.31 (d, J = 7.3 Hz, 1H, CH), 8.50 
(d, J = 8.5 Hz, 1H, CH); δC (100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 40.0, 44.2, 49.4, 53.0, 110.1, 116.9, 
118.8, 122.7, 127.0, 127.5, 127.9, 128.4, 129.0, 129.1, 129.2, 131.9, 132.6, 133.4, 134.9, 135.9, 138.7, 
144.3, 146.8, 147.7, 162.9, 166.7; HRMS (ESI) Calcd for [C41H38F5N3O6S + H] 796.2474 found 796.2488; 







δH (400 MHz, d6-DMSO) 1.28-1.39 (m, 5H, CH2), 1.62 - 1.79 (m, 5H, CH2), 2.37-2.46 (m, 1H, CH), 2.88 (s, 
3H, CH3), 3.95 (s, 2H, CH2), 4.76 (s, 2H, CH2), 6.80 (d of d, J = 8.4 and 2.4 Hz, 1H, CH), 6.88 (d, J = 2.0 
Hz, 1H, CH), 7.02 (d, J = 8.0 Hz, 2H, CH), 7.08 (d, J = 8.0 Hz, 2H, CH), 7.62 - 7.73 (m, 3H, CH), 7.79 (d, J 
= 8.4 Hz, 1H, CH), 8.04 (d, J = 8.4 Hz, 1H, CH), 8.09 (d, J = 8.8 Hz, 1H, CH), 8.12 (d, J = 8.0 Hz, 1H, 
CH), 8.35 (d, J = 1.6 Hz, 1H, CH); δC (100 MHz, d6-DMSO) 25.4, 26.2, 33.8, 35.9, 43.2, 50.8, 51.5, 112.5, 
116.0, 118.5, 119.9, 122.5, 126.5, 127.4, 127.7, 127.8, 128.7, 129.1, 131.3, 131.6, 134.1, 134.2, 135.1, 
146.3, 146.8, 161.5, 166.5, 171.1; HRMS (ESI+) calcd for [C29H31FN2O6S + H] 555.1959, Found 555.1954; 








δH (400 MHz, d-CDCl3) 1.29-1.46 (m, 5H, CH2), 1.67-1.91 (m, 5H, CH2), 2.40-2.53 (m, 1H, CH), 2.91 (s, 
3H, CH3), 3.94 (s, 2H, CH2), 4.79 (s, 2H, CH2), 6.58 (d, J = 8.0 Hz, 1H, CH), 6.70 (s, 1H, CH), 7.04 (d, J = 
7.8 Hz, 2H, CH), 7.11 (d, J = 7.8 Hz, 2H, CH), 7.72 (d, J = 8.0 Hz, 2H, CH), 7.86-7.97 (m, 3H, CH); δC 
(100 MHz, d-CDCl3) 26.1, 26.9, 34.4, 35.8, 44.0, 51.5, 53.1, 112.8, 116.7, 118.7, 121.8, 124.5, 125.9, 125.9, 
126.9, 127.9, 128.3, 132.4, 133.2, 133.9, 134.2, 142.0, 146.9, 147.7, 162.7, 166.8, 172.8, 177.4; HRMS 
(ESI+) calcd for [C30H31F3N2O6S + H] 605.1927, Found 605.1924; HPLC (III) tR = 25.75 min (100 %), (II) 








δH (400 MHz, d-CDCl3) 1.30-1.45 (m, 5H, CH2), 1.69-1.91 (m, 5H, CH2), 2.39-2.52 (m, 1H, CH), 3.82 (s, 
2H, CH2), 4.70 (s, 2H, CH2), 4.78 (s, 2H, CH2), 6.37 (s (br), 1H, CH), 6.50 (s, 1H, CH), 6.96 (d, J = 7.8 Hz, 
2H, CH), 7.09 (d, J = 7.8 Hz, 2H, CH), 7.14-7.21 (m, 2H, CH), 7.36 (t, J = 7.5 Hz, 1H, CH), 7.48 (t, J = 7.7 
Hz, 1H, CH), 7.63 (d, J = 7.8 Hz, 1H, CH), 7.69 (d, J = 7.8 Hz, 1H, CH), 7.77 (d, J = 8.2 Hz, 1H, CH), 7.87-
7.98 (m, 2H, CH); δC (100 MHz, d-CDCl3) 26.0, 26.7, 34.2, 44.1, 47.4, 47.7, 52.9, 111.7, 116.0 (d), 116.9, 
118.8, 122.6, 125.3 (q), 125.7 (q), 126.8, 127.7, 128.4, 129.8, 130.3, 130.4, 132.1, 132.3, 133.1, 134.3, 
135.6 (d), 147.6, 162.8, 163.8, 166.2, 172.3; HRMS (ESI+) Calcd for [C36H34F4N2O6S + H] 699.2146 found 







δH (400 MHz, d-CDCl3) 1.31-1.45 (m, 5H, CH2), 1.70-1.94 (m, 5H, CH2), 2.19 (s, 3H, CH3), 2.40-2.56 (m, 
1H, CH), 3.69 (s, 2H, CH2), 4.57 (s, 2H, CH2), 4.65 (s, 2H, CH2), 6.11 (s (br), 1H, CH), 6.35 (s, 1H, CH), 
6.98 (d, J = 7.6 Hz, 2H, CH), 7.00-7.23 (m, 8H, CH), 7.71 (s (br), 1H, CH), 7.86-7.97 (m, 2H, CH); δC (100 
MHz, d-CDCl3) 26.0, 26.7, 34.3, 44.1, 46.8, 49.0, 52.8, 110.4, 115.9 (d), 116.7, 118.6, 126.0, 126.8, 128.4, 
128.5, 129.9, 130.3, 130.4, 130.7, 132.2, 133.3, 135.5 (d), 137.6, 147.6, 162.7, 163.7, 166.2, 166.6, 172.4; 
HRMS (ESI+) Calcd for [C36H37FN2O6S + H] 645.2429 found 645.2411; HPLC (III) tR = 27.08 min (99.7 








δH (400 MHz, d-CDCl3) 1.30-1.43 (m, 5H, CH2), 1.70-1.92 (m, 5H, CH2), 2.40-2.52 (m, 1H, CH), 3.85 (s, 
2H, CH2), 4.69 (s, 2H, CH2), 4.80 (s, 2H, CH2), 6.35 (d, J = 7.4 Hz, 1H, CH), 6.50 (s, 1H, CH), 6.96 (d, J = 
8.0 Hz, 2H, CH), 7.09 (d, J = 8.0 Hz, 2H, CH), 7.38 (t, J = 7.6 Hz, 1H, CH), 7.49 (t, J = 7.5 Hz, 1H, CH), 
7.65 (d, J = 7.8 Hz, 1H, CH), 7.70 (d, J = 7.8 Hz, 1H, CH), 7.74-7.83 (m, 3H, CH), 8.04 (d, J = 8.2 Hz, 2H, 
CH); δC (100 MHz, d-CDCl3) 26.0, 26.7, 34.2, 44.1, 47.5, 47.7, 52.9, 112.0, 116.8, 118.7, 121.9, 122.6, 
124.6, 125.3, 125.8 (m), 126.8, 127.9, 128.1, 128.4, 129.9, 132.2, 132.3, 133.1, 133.9, 134.0, 134.3, 143.2, 
147.7, 162.8, 165.9, 172.1; HRMS (ESI+) Calcd for [C37H34F6N2O6S + H] 749.2114 found 749.2120; HPLC 







δH (400 MHz, d-CDCl3) 1.32-1.49 (m, 5H, CH2), 1.71-1.94 (m, 5H, CH2), 2.23 (s,3H, CH3), 2.42-2.55 (m, 
1H, CH), 3.73 (s, 2H, CH2), 4.63 (s, 2H, CH2), 4.67 (s, 2H, CH2), 6.15 (s (br), 1H, CH), 6.37 (s, 1H, CH), 
6.98 (d, J = 7.8 Hz, 2H, CH), 7.02-7.19 (m, 5H, CH), 7.23 (t, J = 7.8 Hz, 1H, CH), 7.72 (d, J = 8.2 Hz, 1H, 
CH), 7.79 (d, J = 8.2 Hz, 2H, CH), 8.04 (d, J = 8.0 Hz, 2H, CH); δC (100 MHz, d-CDCl3) 18.8, 26.0, 26.7, 
34.3, 44.1, 46.9, 49.1, 52.9, 111.6, 116.8, 118.8, 121.9, 124.6, 125.8, 125.8, 126.1, 126.8, 128.1, 128.5, 
130.0, 130.8, 131.8, 132.1, 133.1, 133.8, 134.2, 137.7, 143.1, 147.1, 147.7, 162.7, 166.4, 172.4; HRMS 
(ESI+) Calcd for [C37H37F3N2O6S + H] 695.2397 found 695.2417; HPLC (III) tR = 28.07 min (100 %), (II) 
tR = 62.81 min (100 %). 
 
